United States Therapeutic Apheresis Market to Reach $103 Million by 2012, According to New Report by Global Industry Analysts, Inc.

Share Article

United States therapeutic apheresis market is forecast to reach $103 million by 2012. Increasing alliances and agreements and research for new procedures and more sophisticated applications would drive future growth of the market.

Therapeutic Apheresis: A US Market Report

Although therapeutic apheresis is a potential market, soaring treatment costs and lack of awareness debilitate its growth. However, with increasing alliances and agreements, research for new procedures and more sophisticated applications underway, apheresis technology is likely to have major market opportunities for supplies, services and equipment. Reimbursement policies of both government and private insurance companies play a major role in the increase of therapeutic application in several diseases. Emerging applications of therapeutic apheresis in Autoimmune Diseases, Refractory Chronic GvHD, Lupus Erythematosus, Hyperlipidemia, Atherosclerosis and Renal Diseases are forecast to bolster volumes of growth. The untapped pediatric segment is likely to be a potential opportunity to expand the therapeutic apheresis market.

The United States Therapeutic apheresis market is forecast to witness healthy growth and reach US$103 million by 2012, as stated by Global Industry Analysts, Inc. Accounting for an estimated 39% share in 2008, photopheresis market represents the largest as well as the fastest-growing therapeutic apheresis procedure. Plasmapheresis market represents the second largest segment with revenues estimated to exceed US$22.4 million in 2008. Erythrocytapheresis and Plateletpheresis are the other significant procedures, which are gaining impetus for the therapeutic apheresis market.

In terms of end-use, hematology and oncology is the single-largest market for therapeutic apheresis, accounting for an estimated 54% share in 2008. Rheumatology market represents the fastest growing end-use market for therapeutic apheresis, registering a CAGR of 7.3% over the 2000-2010 period.

The US therapeutic apheresis market is oligopolistic in nature dominated by a few large players. Pricing pressures and high research & development costs are leading to market restructuring. Leading players operating in the market include Baxter, Fresenius Medical Care, Haemonetics, HemaCare, and Therakos among others.

The report titled "Therapeutic Apheresis: A US Market Report" published by Global Industry Analysts, Inc., explores various strategic areas such as opportunities, growth drivers, market restraints and market challenges in the US. The report analyzes the market by procedure, namely Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis. Application areas analyzed include Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders, and Others. Future market directions are discussed in detail. Profiles of leading players, their strategies and market shares are covered to provide a competitive insight. Recent corporate developments and technological developments are discussed in the study.

For more details about this research report, please visit http://www.strategyr.com/Therapeutic_Apheresis_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press @ strategyR.com
Web Site http://www.strategyr.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website